FDA Chief to Depart After Trump Signed Off on Oust
FDA chief to depart after Trump – President Donald Trump has given the green light for the resignation of Food and Drug Administration (FDA) Commissioner Marty Makary, according to three individuals who are well-informed about the situation. The decision, finalized last week, marks the end of Makary’s tenure in the Trump administration, with his exit confirmed as a result of internal pressure and disagreements over key policy decisions. Trump’s approval of the move was publicly acknowledged in a recent post on Truth Social, where he announced the selection of Kyle Diamantas, a deputy commissioner overseeing the agency’s food programs, to take over as acting FDA head.
Pressure From Within and Outside the Administration
Makary faced mounting criticism both from within and outside the Trump administration. His resistance to approving the sale of flavored e-cigarettes became a major point of contention, leading to direct confrontations with Trump. This issue, which sparked intense debate, was one of several factors contributing to his ouster. Additionally, the FDA chief endured constant staff changes in the agency’s upper echelons, further destabilizing his leadership. The administration’s internal factions, along with external allies such as pharmaceutical companies and anti-abortion groups, played a role in the decision to remove him.
Outside the FDA, pharmaceutical industry representatives and anti-abortion organizations had long expressed dissatisfaction with Makary’s approach. His stance on flavored e-cigarettes, which they viewed as a barrier to industry growth, intensified the pressure. Meanwhile, within the administration, some officials questioned his effectiveness in managing the FDA’s broad responsibilities, including drug approvals, tobacco regulation, and other critical areas. These challenges culminated in a rapid decision to replace him, with Trump’s endorsement accelerating the process.
Leadership Vacuum and Senate Confirmation
Makary’s departure creates another leadership gap in the U.S. Department of Health and Human Services (HHS), where permanent appointments are already scarce. The agency lacks a confirmed leader for the Centers for Disease Control and Prevention (CDC) and a surgeon general, a role traditionally held by the nation’s top medical authority. Trump’s removal of Makary means the president will now need to appoint a new FDA chief, a process that requires Senate approval and could take significant time before the midterms.
Despite the high stakes, Trump’s decision to fire Makary has been framed as necessary by some White House and HHS officials. They argue that the FDA’s recent turmoil, including internal conflicts and policy inconsistencies, made his continued leadership untenable. Meanwhile, others in the administration cautioned against further destabilizing the health team, fearing it might alienate Trump’s core supporters, particularly those aligned with the “Make America Healthy Again” campaign. The timing of the move also raises questions about its strategic intent, as Makary was set to testify before the Senate Appropriations Committee about the FDA’s proposed budget just one day before his resignation was finalized.
“He doesn’t want to approve youth-appealing flavors, but has been forced to by the powers that be,”
as stated by an insider with knowledge of Makary’s departure. This quote highlights the central conflict: Makary’s desire to protect public health, particularly among younger demographics, clashed with the administration’s priorities. His reversal on flavored e-cigarettes last week underscored the pressure he faced to align with political objectives.
Political Implications and Agency Restructuring
The push to oust Makary gained momentum in recent days, driven by a group of White House and HHS officials who had grown frustrated with the FDA’s dysfunction. These individuals saw Makary’s removal as an opportunity to restructure the agency’s leadership and improve relations with key constituencies, such as the anti-abortion movement and the pharmaceutical industry. This restructuring could include changes to the FDA’s senior staff, aiming to streamline operations and ensure alignment with Trump’s broader health agenda.
While the immediate impact of Makary’s exit is clear, the long-term consequences remain uncertain. His departure signals a shift in the FDA’s approach, potentially prioritizing political considerations over scientific independence. The agency’s role in regulating drugs, devices, and vaccines has been a focal point of Makary’s tenure, but his frequent clashes with industry stakeholders and internal disagreements have left it in a state of flux. With the Senate now tasked with confirming a new FDA leader, the administration’s ability to shape policy will depend on the next appointee’s ability to navigate the complex landscape of healthcare regulation.
A Leader in Controversy
Makary, a surgeon and author, was confirmed as FDA commissioner in March 2025 with a mandate to expedite decisions on medical products. However, his time in office has been marked by controversy. Pharmaceutical companies criticized his management of the drug approval process, while Trump advisors raised concerns about his handling of tobacco regulations and other policy areas. The recent reversal on flavored e-cigarettes, which he initially opposed, has been cited as a turning point in his leadership.
During a critical meeting last week, Trump directly confronted Makary about the vape issue, according to two people close to the event. This confrontation reflected the growing impatience within the administration to see the FDA act in line with their goals. Makary had previously sought to reassure Trump of his loyalty, telling associates he believed the president still supported him. But when reports surfaced on Friday that Trump had approved his removal, the situation quickly shifted. The administration’s factions were left debating the source of the decision and its timing, with some questioning whether Makary’s departure was a calculated move or a result of internal strife.
As the FDA prepares for a new era under Diamantas, the agency’s future will be shaped by the balance between regulatory rigor and political influence. Makary’s exit underscores the challenges of maintaining independence in a government where policy decisions are often intertwined with partisan agendas. The HHS department, already grappling with leadership vacancies, will now face the added complexity of replacing another high-profile official. This move also raises questions about the stability of the administration’s health initiatives and the potential for further shifts in regulatory priorities ahead of the November elections.
In the broader context, the FDA’s role as a watchdog for public health remains vital. Makary’s departure could signal a new direction for the agency, one that emphasizes industry interests and political alignment over scientific consensus. As the Senate considers his replacement, the implications for future drug approvals, tobacco regulations, and abortion access will be closely watched. The decision to remove Makary reflects not only the tensions within the Trump administration but also the broader struggle to maintain consistency in regulatory leadership amid shifting priorities and external pressures.
